Circulating levels of C-reactive protein, interleukin-6 and tumor necrosis factor-α and risk of colorectal adenomas: a meta-analysis

Abstract

Results from publications on inflammatory markers of C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) and risk of colorectal adenomas are not consistent. A meta-analysis was conducted to explore the above-mentioned associations. Relevant studies were identified by a search of Embase, Medline and PubMed through February 2016. A random effect model was adopted to combine study-specific odds ratio (OR) and 95% confidence interval (95% CI). Between-study heterogeneity and publications bias were assessed. Dose–response relationships were assessed by restricted cubic splines. Nineteen observational studies were included. For highest vs. lowest levels, results from this meta-analysis did not support an association between circulating levels of CRP [OR (95% CI): 1.15 (0.94-1.40)], IL-6 [1.17 (0.94-1.46)] and TNF-α [0.99 (0.75-1.31)] and risk of colorectal adenomas, respectively. The findings were supported by sensitivity analysis and subgroup analysis. In dose-response analysis, the risk of colorectal adenomas increased by 2% [1.02 (0.97-1.08)] for each 1 mg/L increment in circulation CRP levels, 9% [1.09 (0.91-1.31)] for each 1 ng/L increment in circulation IL-6 levels, and 6% [1.06 (0.93-1.21)] for each 1 pg/mL increment in circulation TNF-α levels. Moderate between-study heterogeneity was found. No evidence of publication bias was found. Circulation levels of CRP, IL-6 and TNF-α might be not useful biomarkers for identifying colorectal adenomas, respectively.

TNF-Stimulated Gene-6 Is a Key Regulator in Switching Stemness and Biological Properties of Mesenchymal Stem Cells

“…Given the high levels of IL‐6 produced in TSG‐6 −/− ‐MSCs, it was of interest to determine whether the loss of TSG‐6 could sustain pro‐tumoral effects of MSCs. To investigate this possibility, we exploited the effect of MSCs on tumor development in a colitis‐associated model of CRC in which IL‐6 has profound impact on tumorigenesis . Interestingly, we observed that mice receiving allogeneic TSG‐6 −/− ‐MSCs displayed a significant increased number of tumor lesions compared with either untreated (phosphate‐buffered saline [PBS]) or WT‐MSCs‐treated groups, as determined by endoscopic and histological recordings (Fig.…”

Predictive value of inflammatory markers for cancer diagnosis in primary care: a prospective cohort study using electronic health records

“…7 This practice is largely unsupported by evidence; inflammatory markers are not recognised within current guidelines for cancer diagnosis, 8 with the exception of myeloma, where first line tests include ESR or PV. Cohort studies in the general population (irrespective of symptoms) have examined the association between raised CRP and risk of future cancer, 9–11 including meta-analyses of the risk of future colorectal, 12,13 lung, 14 ovarian 15 and breast cancer. 16,17 However, the associations are not strong enough to be clinically useful for identification of symptomatic cancer.…”

Oncomir  Microrna-346  is Upregulated  in Ascending but Not Sigmoid Colon in Patients with Primary Sclerosing Cholangitis with Concurrent Ulcerative Colitis.

“…Association between chronic inflammation and the risk of colorectal cancer remains controversial. Several recent meta-analyses showed no evidence of the association between circulation level of TNF-α and the risk of colorectal cancer [38,39].…”